This prospective study reports 15-year survival and 10-year functional outcomes for 1000 consecutive minimally invasive Phase 3 Oxford medial UKAs performed for anteromedial osteoarthritis or spontaneous osteonecrosis of the knee. It asks whether the excellent long-term results seen with open Oxford UKA are reproducible through a minimally invasive approach at the 15-year mark.
5 mm bearing → 75% 15-year survival
The traditional hesitation around UKA has been durability — the fear that disease will progress and the implant will fail within a decade, leaving a difficult revision. This paper directly confronts that concern with 15-year data on 1000 consecutive cases.
When you see a patient with anteromedial OA (bone-on-bone medially, full-thickness lateral cartilage, intact ACL and MCL), UKA is a legitimate long-term solution — not a bridge procedure. Age, obesity, chondrocalcinosis, and patellofemoral degeneration without lateral bone loss are not disqualifiers for the Oxford device.
When a patient with an Oxford UKA develops lateral compartment OA years later, the right move is lateral UKA addition, not automatic revision to TKA. The medial component is almost certainly still functioning well.
If you see a radiolucent line under the tibial component on plain radiograph, do not reflexively call it loosening: physiological radiolucency (up to 2 mm with a sclerotic border) has no functional consequence and no bearing on outcome.
This prospective study reports 15-year survival and 10-year functional outcomes for 1000 consecutive minimally invasive Phase 3 Oxford medial UKAs performed for anteromedial osteoarthritis or spontaneous osteonecrosis of the knee. It asks whether the excellent long-term results seen with open Oxford UKA are reproducible through a minimally invasive approach at the 15-year mark.
5 mm bearing → 75% 15-year survival
The traditional hesitation around UKA has been durability — the fear that disease will progress and the implant will fail within a decade, leaving a difficult revision. This paper directly confronts that concern with 15-year data on 1000 consecutive cases.
When you see a patient with anteromedial OA (bone-on-bone medially, full-thickness lateral cartilage, intact ACL and MCL), UKA is a legitimate long-term solution — not a bridge procedure. Age, obesity, chondrocalcinosis, and patellofemoral degeneration without lateral bone loss are not disqualifiers for the Oxford device.
When a patient with an Oxford UKA develops lateral compartment OA years later, the right move is lateral UKA addition, not automatic revision to TKA. The medial component is almost certainly still functioning well.
If you see a radiolucent line under the tibial component on plain radiograph, do not reflexively call it loosening: physiological radiolucency (up to 2 mm with a sclerotic border) has no functional consequence and no bearing on outcome.